End-of-day quote
Shanghai S.E.
18:00:00 2024-04-25 EDT
|
5-day change
|
1st Jan Change
|
6.03
CNY
|
+1.52%
|
|
+3.25%
|
-13.98%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
4,101
|
6,094
|
5,046
|
5,013
|
4,942
|
4,535
|
Enterprise Value (EV)
1 |
2,207
|
4,699
|
3,899
|
3,727
|
3,697
|
3,141
|
P/E ratio
|
15.1
x
|
157
x
|
70.9
x
|
70.5
x
|
-95.5
x
|
140
x
|
Yield
|
2.05%
|
0.32%
|
0.71%
|
0.71%
|
0.39%
|
0.43%
|
Capitalization / Revenue
|
1.48
x
|
3.69
x
|
4.82
x
|
4.3
x
|
5.81
x
|
4
x
|
EV / Revenue
|
0.79
x
|
2.84
x
|
3.73
x
|
3.2
x
|
4.35
x
|
2.77
x
|
EV / EBITDA
|
5.13
x
|
48.2
x
|
21.5
x
|
16.6
x
|
54.8
x
|
13
x
|
EV / FCF
|
20
x
|
8.17
x
|
-8.44
x
|
32.4
x
|
62.4
x
|
43.5
x
|
FCF Yield
|
4.99%
|
12.2%
|
-11.8%
|
3.09%
|
1.6%
|
2.3%
|
Price to Book
|
0.92
x
|
1.41
x
|
1.16
x
|
1.15
x
|
1.17
x
|
1.09
x
|
Nbr of stocks (in thousands)
|
646,875
|
646,875
|
646,875
|
646,875
|
646,875
|
646,875
|
Reference price
2 |
6.340
|
9.420
|
7.800
|
7.750
|
7.640
|
7.010
|
Announcement Date
|
19-04-11
|
20-04-16
|
21-04-14
|
22-04-29
|
23-04-12
|
24-04-12
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
2,776
|
1,653
|
1,046
|
1,166
|
850
|
1,134
|
EBITDA
1 |
430.2
|
97.51
|
181.5
|
224.1
|
67.53
|
240.9
|
EBIT
1 |
341.4
|
-5.288
|
40.21
|
79.57
|
-79.06
|
92.71
|
Operating Margin
|
12.3%
|
-0.32%
|
3.84%
|
6.83%
|
-9.3%
|
8.18%
|
Earnings before Tax (EBT)
1 |
365.3
|
49.44
|
90.41
|
113.5
|
-59.57
|
65.04
|
Net income
1 |
272.9
|
36.62
|
70.63
|
69.46
|
-52.02
|
31.66
|
Net margin
|
9.83%
|
2.22%
|
6.75%
|
5.96%
|
-6.12%
|
2.79%
|
EPS
2 |
0.4200
|
0.0600
|
0.1100
|
0.1100
|
-0.0800
|
0.0500
|
Free Cash Flow
1 |
110.1
|
575.3
|
-461.8
|
115.1
|
59.27
|
72.21
|
FCF margin
|
3.97%
|
34.8%
|
-44.14%
|
9.87%
|
6.97%
|
6.37%
|
FCF Conversion (EBITDA)
|
25.6%
|
590%
|
-
|
51.35%
|
87.76%
|
29.98%
|
FCF Conversion (Net income)
|
40.36%
|
1,570.79%
|
-
|
165.66%
|
-
|
228.1%
|
Dividend per Share
2 |
0.1300
|
0.0300
|
0.0550
|
0.0550
|
0.0300
|
0.0300
|
Announcement Date
|
19-04-11
|
20-04-16
|
21-04-14
|
22-04-29
|
23-04-12
|
24-04-12
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
1,894
|
1,395
|
1,147
|
1,286
|
1,245
|
1,394
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
110
|
575
|
-462
|
115
|
59.3
|
72.2
|
ROE (net income / shareholders' equity)
|
6.22%
|
0.85%
|
1.64%
|
1.61%
|
-1.2%
|
0.75%
|
ROA (Net income/ Total Assets)
|
3.66%
|
-0.05%
|
0.4%
|
0.82%
|
-0.84%
|
1.02%
|
Assets
1 |
7,449
|
-68,586
|
17,796
|
8,522
|
6,226
|
3,115
|
Book Value Per Share
2 |
6.860
|
6.670
|
6.710
|
6.730
|
6.510
|
6.460
|
Cash Flow per Share
2 |
2.110
|
2.430
|
2.560
|
1.800
|
2.000
|
1.770
|
Capex
1 |
17
|
752
|
148
|
78.3
|
35
|
145
|
Capex / Sales
|
0.61%
|
45.48%
|
14.13%
|
6.72%
|
4.12%
|
12.82%
|
Announcement Date
|
19-04-11
|
20-04-16
|
21-04-14
|
22-04-29
|
23-04-12
|
24-04-12
|
|
1st Jan change
|
Capi.
|
---|
| -13.98% | 538M | | +25.83% | 661B | | +27.36% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +14.49% | 231B | | +4.69% | 200B | | -9.33% | 195B | | -6.26% | 145B |
Other Pharmaceuticals
|